PL3033101T3 - Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu - Google Patents

Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu

Info

Publication number
PL3033101T3
PL3033101T3 PL14835826T PL14835826T PL3033101T3 PL 3033101 T3 PL3033101 T3 PL 3033101T3 PL 14835826 T PL14835826 T PL 14835826T PL 14835826 T PL14835826 T PL 14835826T PL 3033101 T3 PL3033101 T3 PL 3033101T3
Authority
PL
Poland
Prior art keywords
benralizumab
asthma
methods
exacerbation rates
reducing exacerbation
Prior art date
Application number
PL14835826T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3033101T3 publication Critical patent/PL3033101T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
PL14835826T 2013-08-12 2014-08-07 Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu PL3033101T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
EP14835826.0A EP3033101B1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (1)

Publication Number Publication Date
PL3033101T3 true PL3033101T3 (pl) 2019-06-28

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14835826T PL3033101T3 (pl) 2013-08-12 2014-08-07 Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu

Country Status (26)

Country Link
US (2) US9441037B2 (pl)
EP (1) EP3033101B1 (pl)
JP (4) JP6746495B2 (pl)
KR (2) KR20220057637A (pl)
CN (2) CN111588848A (pl)
AU (2) AU2014306956B2 (pl)
BR (1) BR112016002401A8 (pl)
CA (1) CA2918105C (pl)
CY (1) CY1122132T1 (pl)
DK (1) DK3033101T3 (pl)
ES (1) ES2716906T3 (pl)
HK (2) HK1221644A1 (pl)
HR (1) HRP20190405T1 (pl)
HU (1) HUE042607T2 (pl)
LT (1) LT3033101T (pl)
ME (1) ME03348B (pl)
MX (1) MX368508B (pl)
PL (1) PL3033101T3 (pl)
PT (1) PT3033101T (pl)
RS (1) RS58404B1 (pl)
RU (1) RU2676333C2 (pl)
SG (2) SG11201600481UA (pl)
SI (1) SI3033101T1 (pl)
SM (1) SMT201900163T1 (pl)
TR (1) TR201903312T4 (pl)
WO (1) WO2015023504A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043497T2 (hu) 2013-08-12 2019-08-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
TR201910413T4 (tr) * 2013-08-12 2019-08-21 Astrazeneca Ab Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
CN113230399A (zh) * 2013-10-15 2021-08-10 阿斯利康(瑞典)有限公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
CN113350278B (zh) * 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
RU2693084C2 (ru) 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
CA3002761A1 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
WO2018127830A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
MX2012005661A (es) * 2009-11-18 2012-09-07 Medicinova Inc Tratamiento de exacerbacion aguda de asma y reduccion de probabilidad de hospitalizacion de pacientes que sufren de la misma.
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
HUE043497T2 (hu) 2013-08-12 2019-08-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
TR201910413T4 (tr) 2013-08-12 2019-08-21 Astrazeneca Ab Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.

Also Published As

Publication number Publication date
RU2016108723A3 (pl) 2018-06-18
EP3033101B1 (en) 2018-12-19
JP6746495B2 (ja) 2020-08-26
MX368508B (es) 2019-10-07
SI3033101T1 (sl) 2019-04-30
ME03348B (me) 2019-10-20
EP3033101A4 (en) 2017-07-12
WO2015023504A8 (en) 2015-09-24
HRP20190405T1 (hr) 2019-04-19
SMT201900163T1 (it) 2019-05-10
KR102390714B1 (ko) 2022-04-26
PT3033101T (pt) 2019-04-02
KR20220057637A (ko) 2022-05-09
EP3033101A1 (en) 2016-06-22
SG10202005560UA (en) 2020-07-29
CA2918105C (en) 2023-02-28
HK1225302B (en) 2017-09-08
CN111588848A (zh) 2020-08-28
CN105451760A (zh) 2016-03-30
US9441037B2 (en) 2016-09-13
AU2014306956A1 (en) 2016-02-04
LT3033101T (lt) 2019-03-25
BR112016002401A2 (pt) 2017-09-12
WO2015023504A1 (en) 2015-02-19
JP2022120009A (ja) 2022-08-17
RU2016108723A (ru) 2017-09-19
US20150044202A1 (en) 2015-02-12
CY1122132T1 (el) 2020-11-25
JP2020128375A (ja) 2020-08-27
KR20160042121A (ko) 2016-04-18
RS58404B1 (sr) 2019-04-30
US20170198049A1 (en) 2017-07-13
CA2918105A1 (en) 2015-02-19
DK3033101T3 (en) 2019-04-08
BR112016002401A8 (pt) 2018-06-12
HK1221644A1 (zh) 2017-06-09
RU2676333C2 (ru) 2018-12-28
AU2020201327A1 (en) 2020-03-12
HUE042607T2 (hu) 2019-07-29
JP2024129139A (ja) 2024-09-26
AU2014306956B2 (en) 2019-11-21
TR201903312T4 (tr) 2019-04-22
SG11201600481UA (en) 2016-02-26
ES2716906T3 (es) 2019-06-17
MX2016001383A (es) 2016-08-03
JP2016527324A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
SG10202005560UA (en) Methods for reducing exacerbation rates of asthma using benralizumab
IL240215A0 (en) Methods for the purification of messenger RNA
SI3305778T1 (sl) Zaviralci plazemskega kalikreina
HUE14755117T2 (hu) Plazma-kallikrein inhibitorok
HUE073609T2 (hu) Bipirazol-származékok mint jak-gátlók
GB201401248D0 (en) Method of manufacture
PL3033332T3 (pl) Bicykliczne inhibitory kalikreiny osoczowej
SG11201600484TA (en) Methods for improving asthma symptoms using benralizumab
EP3123173A4 (en) Methods for suppressing cancer by inhibition of tmcc3
IL240763B (en) The halopyrazoles as thrombin inhibitors
ZA201507475B (en) Method for the treatment of gas
IL237862A0 (en) Methods to reduce the formation of scale
GB201305231D0 (en) Method of Manufacture
ZA201601775B (en) Method for the synthesis of irinotecan
GB201301125D0 (en) Methods for improving the efficency of gene targeting
PT2799426T (pt) Novo processo para a síntese de aminaftona
SG11201507157YA (en) Method of synthesis
GB201316400D0 (en) Methods, compositions and kits for preparing sequencing library
SG10201701021XA (en) Method of synthesis
GB201319952D0 (en) Methods of isolating ions
GB201308949D0 (en) Compositions and methods for reducing methane production
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture